174 related articles for article (PubMed ID: 23361053)
41. Herstatin inhibits heregulin-mediated breast cancer cell growth and overcomes tamoxifen resistance in breast cancer cells that overexpress HER-2.
Jhabvala-Romero F; Evans A; Guo S; Denton M; Clinton GM
Oncogene; 2003 Nov; 22(50):8178-86. PubMed ID: 14603258
[TBL] [Abstract][Full Text] [Related]
42. p21-activated kinase 1 determines stem-like phenotype and sunitinib resistance via NF-κB/IL-6 activation in renal cell carcinoma.
Zhu Y; Liu H; Xu L; An H; Liu W; Liu Y; Lin Z; Xu J
Cell Death Dis; 2015 Feb; 6(2):e1637. PubMed ID: 25675297
[TBL] [Abstract][Full Text] [Related]
43. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.
Yuan J; Liu M; Yang L; Tu G; Zhu Q; Chen M; Cheng H; Luo H; Fu W; Li Z; Yang G
Breast Cancer Res; 2015 May; 17(1):69. PubMed ID: 25990368
[TBL] [Abstract][Full Text] [Related]
44. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance.
Campbell RA; Bhat-Nakshatri P; Patel NM; Constantinidou D; Ali S; Nakshatri H
J Biol Chem; 2001 Mar; 276(13):9817-24. PubMed ID: 11139588
[TBL] [Abstract][Full Text] [Related]
45. Relevance of BCAR4 in tamoxifen resistance and tumour aggressiveness of human breast cancer.
Godinho MF; Sieuwerts AM; Look MP; Meijer D; Foekens JA; Dorssers LC; van Agthoven T
Br J Cancer; 2010 Oct; 103(8):1284-91. PubMed ID: 20859285
[TBL] [Abstract][Full Text] [Related]
46. Prolactin-induced PAK1 tyrosyl phosphorylation promotes FAK dephosphorylation, breast cancer cell motility, invasion and metastasis.
Hammer A; Diakonova M
BMC Cell Biol; 2016 Aug; 17(1):31. PubMed ID: 27542844
[TBL] [Abstract][Full Text] [Related]
47. Regulation of the ErbB3 binding protein Ebp1 by protein kinase C.
Lessor TJ; Hamburger AW
Mol Cell Endocrinol; 2001 Apr; 175(1-2):185-91. PubMed ID: 11325528
[TBL] [Abstract][Full Text] [Related]
48. Hedgehog signaling is a novel therapeutic target in tamoxifen-resistant breast cancer aberrantly activated by PI3K/AKT pathway.
Ramaswamy B; Lu Y; Teng KY; Nuovo G; Li X; Shapiro CL; Majumder S
Cancer Res; 2012 Oct; 72(19):5048-59. PubMed ID: 22875023
[TBL] [Abstract][Full Text] [Related]
49. Role of RBP2-Induced ER and IGF1R-ErbB Signaling in Tamoxifen Resistance in Breast Cancer.
Choi HJ; Joo HS; Won HY; Min KW; Kim HY; Son T; Oh YH; Lee JY; Kong G
J Natl Cancer Inst; 2018 Apr; 110(4):. PubMed ID: 29028222
[TBL] [Abstract][Full Text] [Related]
50. Cytoplasmic accumulation of the RNA binding protein HuR is central to tamoxifen resistance in estrogen receptor positive breast cancer cells.
Hostetter C; Licata LA; Witkiewicz A; Costantino CL; Yeo CJ; Brody JR; Keen JC
Cancer Biol Ther; 2008 Sep; 7(9):1496-506. PubMed ID: 18769129
[TBL] [Abstract][Full Text] [Related]
51. Tyrosyl phosphorylated PAK1 regulates breast cancer cell motility in response to prolactin through filamin A.
Hammer A; Rider L; Oladimeji P; Cook L; Li Q; Mattingly RR; Diakonova M
Mol Endocrinol; 2013 Mar; 27(3):455-65. PubMed ID: 23340249
[TBL] [Abstract][Full Text] [Related]
52. Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells.
Knowlden JM; Hutcheson IR; Jones HE; Madden T; Gee JM; Harper ME; Barrow D; Wakeling AE; Nicholson RI
Endocrinology; 2003 Mar; 144(3):1032-44. PubMed ID: 12586780
[TBL] [Abstract][Full Text] [Related]
53. Keratinocyte growth factor (KGF) regulates estrogen receptor-alpha (ER-alpha) expression and cell apoptosis via phosphatidylinositol 3-kinase (PI3K)/Akt pathway in human breast cancer cells.
Chang HL; Sugimoto Y; Liu S; Wang LS; Huang YW; Ye W; Lin YC
Anticancer Res; 2009 Aug; 29(8):3195-205. PubMed ID: 19661335
[TBL] [Abstract][Full Text] [Related]
54. Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.
Larsen SL; Yde CW; Laenkholm AV; Rasmussen BB; Duun-Henriksen AK; Bak M; Lykkesfeldt AE; Kirkegaard T
BMC Cancer; 2015 Apr; 15():239. PubMed ID: 25885472
[TBL] [Abstract][Full Text] [Related]
55. p21 activated kinase-1 and tamoxifen - A deadly nexus impacting breast cancer outcomes.
Rajendran S; Swaroop SS; Roy J; Inemai E; Murugan S; Rayala SK; Venkatraman G
Biochim Biophys Acta Rev Cancer; 2022 Jan; 1877(1):188668. PubMed ID: 34896436
[TBL] [Abstract][Full Text] [Related]
56. MCF-7 breast cancer cells selected for tamoxifen resistance acquire new phenotypes differing in DNA content, phospho-HER2 and PAX2 expression, and rapamycin sensitivity.
Leung E; Kannan N; Krissansen GW; Findlay MP; Baguley BC
Cancer Biol Ther; 2010 May; 9(9):717-24. PubMed ID: 20234184
[TBL] [Abstract][Full Text] [Related]
57. Oestrogen receptor-regulated glutathione S-transferase mu 3 expression attenuates hydrogen peroxide-induced cytotoxicity, which confers tamoxifen resistance on breast cancer cells.
Lin JH; Tu SH; Chen LC; Huang CC; Chang HL; Cheng TC; Chang HW; Wu CH; Wu HC; Ho YS
Breast Cancer Res Treat; 2018 Nov; 172(1):45-59. PubMed ID: 30054830
[TBL] [Abstract][Full Text] [Related]
58. β-elemene enhances the radiosensitivity of gastric cancer cells by inhibiting Pak1 activation.
Liu JS; Che XM; Chang S; Qiu GL; He SC; Fan L; Zhao W; Zhang ZL; Wang SF
World J Gastroenterol; 2015 Sep; 21(34):9945-56. PubMed ID: 26379399
[TBL] [Abstract][Full Text] [Related]
59. Stemness Phenotype in Tamoxifen Resistant Breast Cancer Cells May be Induced by Interactions Between Receptor Tyrosine Kinases and ERα-66.
Farahmand L; Mansouri S; Jafarbeik-Iravani N; Teymourzadeh A; Majidzadeh-A K
Recent Pat Anticancer Drug Discov; 2018; 13(3):302-307. PubMed ID: 29512469
[TBL] [Abstract][Full Text] [Related]
60. Anti-cancer effect of metformin by suppressing signaling pathway of HER2 and HER3 in tamoxifen-resistant breast cancer cells.
Kim J; Lee J; Kim C; Choi J; Kim A
Tumour Biol; 2016 May; 37(5):5811-9. PubMed ID: 26581908
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
